RunaPharma
ActiveSummary
RunaPharma has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€18,060) and a net result of -€1,293. Equity is shrinking by about 8.3% per year across the filed financial years. Its solvency ranks better than 5% of 2,778 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
15-03
Gazette deed
Resignation: VAN DER AUWERA Lodewijk Bertha Theophiel (director)Appointment: VAN DER AUWERA Lodewijk Bertha Theophiel (director) · Capital conversion · Reserve release12 facts ▸
- General meeting, 04-03-2024
- Capital conversion, “onbeschikbare eigenvermogensrekening” (deed in Dutch)
- Reserve release, “opheffing, beschikbaar voor uitkering” (deed in Dutch)
- Name change, RunaPharma
- Purpose change
- Power of attorney
- Director resignation, VAN DER AUWERA Lodewijk Bertha Theophiel (director)
- Board rule, 1
- Director appointment, VAN DER AUWERA Lodewijk Bertha Theophiel (director (not named in the articles))
- Amendment of the articles
- Other provision, “vermogen” (deed in Dutch)
- Share issue, 200, “vergoeding voor de inbrengen” (deed in Dutch)
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.